Abstract A possible association between end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some but not all studies. We have analyzed the APOE genotypes in 995 hemodialyzed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequency of APOE alleles between cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (P = 0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13-1.67). The strength of the association increased with the time spent on hemodialysis: the odds ratio of all-cause ESRD in patients dialyzed for eight or more years was 1.27 (0.94-1.71), for 1-8 years 1.41 (1.09-1.81), and less than 1 year (nonsurvivors) 1. 94 (0.88-4.18). This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians.
Introduction
End-stage renal disease (ESRD) is a serious health problem worldwide, with more than one million patients requiring renal replacement therapy (Moeller et al. 2002) , and the number of ESRD patients continues to grow. Development of ESRD is a function of both genetic and nongenetic factors. While number of nongenetic factors have already been identified (e.g., hypertension, obesity, smoking, inadequate activation of angiotensin-renin system) (Gross and Amann 2004; Leblanc et al. 2005) , but the genetic factors influencing renal failure are poorly understood (Nordfors et al. 2005) .
Lipid abnormalities are common in patients with ESRD, and these abnormalities may contribute to the progression of renal disease. The most important genetic determinant of plasma cholesterol is the gene for apolipoprotein E (APOE, gene ID 348, OMIM acc. no. 107741). ApoE is a component of triglyceride-rich lipoproteins and a subfraction of high-density lipoproteins. There are three common APOE variants, E2 (Arg158 ? Cys), E3, and E4 (Cys112 ? Arg), and almost 30 APOE mutations (Hubacek et al. 2000) . The different functional properties of the APOE isoforms result in elevated plasma cholesterol in APOE4 allele carriers; the lowest plasma concentrations of cholesterol are found in carriers of the APOE2 allele (Davignon et al. 1988) . However, as the frequencies of individual alleles vary between different populations, mainly because of differences in ethnic background (Hubacek et al. 2000; Davignon et al. 1988; Gerdes et al. 1992; Svobodova et al. 2007) , findings on the associations between genotypes and disease in one population cannot be automatically extrapolated to all other populations.
It is known that APOE is expressed in kidney tissue, but the exact role of apolipoprotein E in the kidney remains unclear. Animal experiments suggest that apolipoprotein E has a protective function, possibly as an autocrine regulator of mesangial expansion and kidney function (Chen et al. 2001 ). In addition, many human APOE mutations have been detected in patients with different types of kidney disease, which may independently contribute to kidney dysfunction (for review see Hubacek et al. 2000; Liberopoulos et al. 2004) . It is therefore plausible that the common APOE variants may play a significant role in kidney disease development.
Several previous studies, using different research designs, have analyzed APOE variants in ESRD patients. These studies, reviewed by Liberopoulos et al. (2004) , suggest that the carriers of the APOE2 allele have higher risk of ESRD development, but the results so far are not conclusive. The major limitation of the previous studies is their low statistical power due to the relatively small number of subjects. The comparison of studies is also complicated by the numerous different causes of ESRD.
In the present study, we have examined the relative frequency of APOE genotypes in patients with all-cause ESRD and compared them with healthy controls drawn from a large population sample of healthy individuals. As this study is much larger than previous investigations, it should provide a statistically more reliable test of the hypothesis that all-cause ESRD is associated with the APOE genotype.
Materials and Methods
We have genotyped 995 adult patients (out of 1014 collected, 565 males and 449 females) with a mean age of 66.9 ± 12.7 years (CR 97.8%), who were undergoing hemodialysis for at least 3 months in 27 hemodialysis units across the Czech Republic; the centers were selected primarily on the basis of their willingness to participate in the study (Hubacek et al. 2007 ). The most common verified causes of end-stage renal failure were diabetic nephropathy (102 cases), chronic tubulointerstitial nephropathy (99), and nephrosclerosis based on hypertension (39). Unfortunately, approximately 40% of the patients with chronic renal failure did not undergo renal biopsy; it was, therefore, not possible to specify the primary cause of the renal disease, which in turn prevented us from analyzing the role of APOE polymorphism and ESRD with regard to the primary disease. Patients were further classified into three groups according to the time spent on hemodialysis treatment ([8 years, 1-7 years, and those who survived for less than 1 year). Limited followup of the patients showed no conversion to the peritoneal dialysis; 78 (7.8%) underwent kidney transplantation.
The healthy controls were participants in a large cohort study, the Czech part of the international project Health, Alcohol, Psychological Factors in Eastern Europe (HAPIEE study; Peasey et al. 2006) . The participants in the HAPIEE study were randomly selected from population registers of seven towns. We have genotyped 6627 individuals (3049 males and 3578 females, mean age 58.3 ± 7.1 years). All patients and healthy controls were of Caucasian ethnicity.
Genomic DNA was isolated from whole blood using the salting out method (Miller et al. 1988 ). Genotyping of APOE was performed as described by Hixson and Vernier (1990) . Because of the low numbers of APOE2E2 and APOE4E4 homozygotes, the subjects were divided into three groups for statistical analysis: (1) carriers of the allele APOE2 (APOE2E2 and APOE3E2 individuals), (2) APOE3E3 homozygotes, and (3) carriers of the allele APOE4 (APOE4E4 and APOE4E3 individuals). Subjects with APOE4E2 genotypes (17 persons, 1.7% from ESRD patients; 130, 2.1% of healthy controls) were excluded from the analysis because of the uncertainty about appropriate pooling with other genotypes. The statistical analysis used chi-square and Fisher exact tests.
Results and Discussion
In both cases and controls, the most common genotype was APOE3E3 (frequency in controls 66.1%, Table 1), and the genotype frequencies were in agreement with Hardy-Weinberg equilibrium. There was a statistically significant difference in the frequency of the APOE genotype between patients with all-cause ESRD and healthy controls (Table 1) , with more carriers of the APOE2 allele in all-cause ESRD patients (15.9%) than in healthy controls (12.2%; P = 0.005). For the three most commonly diagnosed causes of ESRD available in our data, the APOE2 allele frequencies were 13.9% for diabetic nephropathy, 12.5% for chronic tubulointerstitial nephropathy, and 12.8% for nephrosclerosis based on hypertension; none of these frequencies differed significantly from controls. In addition, there were no significant differences in the frequencies of the APOE genotypes by history of ischemic heart disease or diabetes mellitus. The relative frequency of the APOE2 allele carriers increased as survival on hemodialysis decreased (Table 2) ; the odds of dying within 1 year were almost twice as high among carriers of at least one APOE2 allele than among persons with the APOE3E3 genotype (P for trend 0.001).
An association of APOE2 with increased risk of all-cause ESRD is supported by three observations. First, the frequency of the APOE genotypes in our study population was similar to that of the neighboring European populations (Gerdes et al. 1992) . Second, the association was stronger for disease with shorter survival, which might reflect a biological gradient by the severity of the disease (although the primary disease was not known). The presence of the APOE2 allele could potentially affect survival on hemodialysis treatment and perhaps influence the development of malnutrition-inflammation-atherosclerosis syndrome (Pecoits-Filho et al. 2002) . Third, the observed association of the APOE genotype with ESRD is also consistent with some (although not all) previous reports. Case-control studies by Oda et al. (1999) and Horita et al. (1994) in Japan (using cases with or without noninsulin-dependent diabetes mellitus) also found a higher allele frequency of APOE2 in ESRD patients than in healthy populations. We are aware that the literature is not entirely consistent. For example, a study by Roussos et al. (2004) also suggested the involvement of APOE in renal disease, but in their study the implicated allele was the APOE3E4 genotype in a subgroup of ESRD patients with noninsulin-dependent diabetes mellitus; however, they did not observe a higher percentage of APOE2 in their cases, compared with controls. Other studies failed to detect any significant differences in APOE genotypes between patients with kidney disease and controls (Feussner et al. 1992; Güz et al. 2000; Arikan et al. 2007 ). These studies were very small, however, with fewer than 100 cases per study; given their low statistical power and the relatively weak association between ESRD and APOE genotype, false negative results are the most likely explanation.
A major limitation of this study is the lack of information on the primary disease in most of the ESRD patients. It was not possible to analyze the role of the APOE in patients with different primary diagnoses and to establish whether the effect of APOE is specific to a particular primary cause.
This study is the largest to date on the relationship between all-cause ESRD and the APOE genotype. It found a significantly higher frequency of the APOE2 allele carriers in all-cause ESRD patients compared with healthy controls, and this association was stronger in 1-year nonsurvivors. The results suggest that the APOE2 allele is a possible genetic risk factor for development of ESRD in Caucasians.
